Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Q3-2021 Healthcare Staffing Update

Skip to the end of the Expertise Menu

Q3-2021 Healthcare Staffing Update

Previously in Q2, there were several new staffing partnerships including Gifted Healthcare and MAS Medical Staffing who partnered with Brown Brothers Harriman and Periscope Equity, respectively. Travel nursing is still expected to drive most of healthcare staffing growth through year-end, in addition to per diem, locum tenens, and allied.  Growth is estimated at 40%, 15%, 12%, and 10%, respectively, year over year, per Staffing Industry Analysts.

Bill rates appeared to start normalizing however, the delta variant has prevented further normalization. According to Staffing Industry Analysts, 8% of travel nursing firms experienced increased bill rates relative to the previous three months, and 19% of firms surveyed expect rates to decline over the next six months.

The most notable platform announcement in Q3 included Medical Solutions, who partnered with Centerbridge Partners and CDPQ.  Previously under TPG ownership, Medical Solutions primarily focuses on travel nursing and allied staffing.  Notable historical add-on acquisitions include PPR Talent Management Group and C&A Industries.

To print and download the full Healthcare Staffing Update report, please click below…

[holo_button icon=”/wp-content/uploads/2021/10/Q3-2021-Healthcare-Staffing-Newsletter.pdf” link=”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]


Sources: SEC Filings; Company Press Releases, and Reports; IBISWorld; Capital IQ; PHP Estimates and Research. This document has been compiled with publicly available information. Provident Healthcare Partners, LLC makes no guarantee of its accuracy or completeness. No data or statement should be construed to be a recommendation for the purchase, sale, or retention of any security.